Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
370 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Merck & Co., Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Merck & Co., Inc. - Product Pipeline Review - 2015', provides an overview of the Merck & Co., Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Merck & Co., Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Merck & Co., Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Merck & Co., Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Merck & Co., Inc.'s pipeline products Reason To Buy - Evaluate Merck & Co., Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Merck & Co., Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Merck & Co., Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Merck & Co., Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck & Co., Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Merck & Co., Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Merck & Co., Inc. Snapshot 8 Merck & Co., Inc. Overview 8 Key Information 8 Key Facts 8 Merck & Co., Inc. - Research and Development Overview 9 Key Therapeutic Areas 9 Merck & Co., Inc. - Pipeline Review 20 Pipeline Products by Stage of Development 20 Pipeline Products - Monotherapy 21 Pipeline Products - Combination Treatment Modalities 22 Pipeline Products - Partnered Products 23 Pipeline Products - Out-Licensed Products 26 Merck & Co., Inc. - Pipeline Products Glance 29 Merck & Co., Inc. - Late Stage Pipeline Products 29 Merck & Co., Inc. - Clinical Stage Pipeline Products 33 Merck & Co., Inc. - Early Stage Pipeline Products 37 Merck & Co., Inc. - Unknown Stage Pipeline Products 40 Merck & Co., Inc. - Drug Profiles 41 (ceftolozane sulfate + tazobactam sodium) 41 (lamivudine + raltegravir potassium) 43 diquafosol tetrasodium 44 human papillomavirus (9-valent) vaccine 46 omarigliptin 48 pembrolizumab 50 sugammadex sodium 56 tedizolid phosphate 58 corifollitropin alfa 60 (actoxumab + bezlotoxumab) 62 (doravirine + lamivudine + tenofovir disoproxil fumarate) 63 (ertugliflozin + metformin) 64 (ertugliflozin + sitagliptin) 65 (etoricoxib + tizanidine) 66 (grazoprevir + elbasvir) 67 actoxumab 69 anacetrapib 70 aprepitant 72 asenapine maleate 74 bevenopran 75 bezlotoxumab 77 desloratadine 78 doravirine 79 fidaxomicin 80 insulin glargine 83 letermovir 85 MK-8237 86 MK-8931 88 odanacatib 89 posaconazole 91 rituximab biosimilar 92 solithromycin 93 surotomycin 95 V-212 96 V-920 98 vibegron 101 vorinostat 102 BQ-123 106 dalotuzumab 108 grazoprevir 111 lomerizine 113 lonafarnib 114 mirtazapine ODT 116 MK-1029 117 MK-2206 118 MK-2206 + selumetinib sulfate 121 MK-7622 123 MK-8342B 124 MK-8628 125 narlaprevir 127 relebactam 128 samatasvir 130 temozolomide 132 V-114 134 MK-3682 135 CB-618 136 MK-0752 137 MK-1075 138 MK-2048 139 MK-2248 140 MK-2640 141 MK-4166 142 MK-7680 143 MK-8150 144 MK-8189 145 MK-8242 146 MK-8291 148 MK-8408 149 MK-8507 150 MK-8521 151 MK-8591 152 MK-8666 153 MK-8723 154 MK-8876 155 Monoclonal Antibody for Autoimmune Diseases 156 NB-1008 157 SCH-772984 158 Small Molecule 1 for Human Cytomegalovirus Infection 159 Small Molecule 2 for Human Cytomegalovirus Infection 160 V-160 161 V-180 162 BNC-375 163 CB-027 164 chikungunya vaccine 165 DORA-12 166 Drug to Inhibit 11Beta-HSD1 for Hypertension 167 Drugs to Inhibit CYP11B2 for Cardiovascular Diseases 168 ETP-142 169 GP-4 170 GRA-1 171 J8-CRM197 172 M-867 173 mDX-400 174 MK-4256 175 MK-8745 176 MK-8825 177 MK-8970 178 Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 179 MRK-003 180 Oligonucleotides for Viral Infections 181 OTX-009 182 Proteins for Cancer, Autoimmune and Inflammatory diseases 183 PTC-512 184 PTC-725 185 PTC-971 186 respiratory syncytial virus vaccine 187 SCH-412348 189 SCH-546738 190 Small Molecule 3 for Human Cytomegalovirus Infection 191 Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 192 Small Molecule to Inhibit JAK2 for Myeloproliferative Disorder 193 Small Molecule to Inhibit Kinesin Spindle Protein for Cancer 194 Small Molecule to Inhibit PLK1 for Cancer 195 Small Molecules for Atherosclerosis 196 Small Molecules to Agonize M1 for Alzheimer's Disease 197 Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 199 Small Molecules to Block Cav2.2 Channel for Chronic Pain 200 Small Molecules to Inhibit DHFR for Septicaemia 201 Small Molecules to Inhibit NS5B Polymerase for Hepatitis C 202 Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 203 THPP-1 204 TROX-1 205 XEN-445 206 XL-499 207 Biosimilars for Undisclosed Indication 208 Drug to Target GPCR for Undisclosed Indication 209 hepatitis C vaccine 210 Kibdelomycin A 211 Monoclonal Antibodies for Undisclosed Indication 212 Monoclonal Antibody for Cancer 213 Monoclonal Antibody for Neurology 214 SCH-722984 215 Small Molecules for Undisclosed Indication 216 Small Molecules to Inhibit CGRP Receptor for Migraine 217 Small Molecules to Inhibit DGAT1 for Undisclosed Indication 218 Small Molecules to Inhibit Renin for Undisclosed Indication 219 Small Molecules to Activate sGC for Cardiovascular Disease 220 Merck & Co., Inc. - Pipeline Analysis 221 Merck & Co., Inc. - Pipeline Products by Target 221 Merck & Co., Inc. - Pipeline Products by Route of Administration 227 Merck & Co., Inc. - Pipeline Products by Molecule Type 228 Merck & Co., Inc. - Pipeline Products by Mechanism of Action 230 Merck & Co., Inc. - Recent Pipeline Updates 235 Merck & Co., Inc. - Dormant Projects 298 Merck & Co., Inc. - Dormant Projects 298 Merck & Co., Inc. - Discontinued Pipeline Products 306 Discontinued Pipeline Product Profiles 308 Merck & Co., Inc. - Company Statement 319 Merck & Co., Inc. - Locations And Subsidiaries 322 Head Office 322 Other Locations & Subsidiaries 322 Appendix 358 Methodology 358 Coverage 358 Secondary Research 358 Primary Research 358 Expert Panel Validation 358 Contact Us 358 Disclaimer 359
List of Tables
Merck & Co., Inc., Key Information 19 Merck & Co., Inc., Key Facts 19 Merck & Co., Inc. - Pipeline by Indication, 2015 21 Merck & Co., Inc. - Pipeline by Stage of Development, 2015 31 Merck & Co., Inc. - Monotherapy Products in Pipeline, 2015 32 Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2015 33 Merck & Co., Inc. - Partnered Products in Pipeline, 2015 34 Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2015 35 Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2015 37 Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 38 Merck & Co., Inc. - Pre-Registration, 2015 40 Merck & Co., Inc. - Filing rejected/Withdrawn, 2015 41 Merck & Co., Inc. - Phase III, 2015 42 Merck & Co., Inc. - Phase II, 2015 44 Merck & Co., Inc. - Phase I, 2015 46 Merck & Co., Inc. - Preclinical, 2015 48 Merck & Co., Inc. - Discovery, 2015 50 Merck & Co., Inc. - Unknown, 2015 51 Merck & Co., Inc. - Pipeline by Target, 2015 233 Merck & Co., Inc. - Pipeline by Route of Administration, 2015 238 Merck & Co., Inc. - Pipeline by Molecule Type, 2015 240 Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2015 242 Merck & Co., Inc. - Recent Pipeline Updates, 2015 246 Merck & Co., Inc. - Dormant Developmental Projects,2015 309 Merck & Co., Inc. - Discontinued Pipeline Products, 2015 317 Merck & Co., Inc., Subsidiaries 333
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
